Related Experiment Video
Updated: May 27, 2026
07:30
Design of Cecal Ligation and Puncture and Intranasal Infection Dual Model of Sepsis-Induced Immunosuppression
Published on: June 15, 2019
Immune-modulating interventions in critically ill septic patients: pharmacological options
1Odense University Hospital, DK-5000 Odense C, Denmark.
Expert Review of Clinical Pharmacology
|November 26, 2011
Summary
Developing immune-modulating therapies for severe sepsis has been challenging. While some treatments show promise in animals, clinical results are inconsistent, highlighting the need for better timing and understanding of inflammatory responses.
Area of Science:
- Critical care medicine
- Immunology
- Pharmacology
Background:
- Severe sepsis and septic shock involve complex systemic inflammation with pro- and anti-inflammatory mediators.
- High mortality rates drive the search for effective immune-modulating therapies.
- Decades of research have yielded limited success in improving survival for septic patients.
Purpose of the Study:
- To review the development and efficacy of immune-modulating therapies for severe sepsis.
- To identify discrepancies between preclinical and clinical findings for these interventions.
- To suggest future directions for optimizing sepsis treatment.
Main Methods:
- Review of pharmacological immune-modulating interventions tested in severe sepsis.
- Analysis of studies demonstrating beneficial or detrimental effects on survival.
- Comparison of animal model results with clinical trial outcomes.
Main Results:
- Few immune-modulating agents have consistently improved survival in septic patients.
- Activated protein C and intensive insulin therapy showed initial promise but faced reproducibility issues.
- A significant gap exists between the efficacy observed in animal studies and human clinical trials.
Conclusions:
- Immune-modulating interventions for sepsis have shown inconsistent clinical benefits.
- Reproducibility of positive effects, like those seen with activated protein C, remains a challenge.
- Future research must better define inflammatory response dynamics and optimize treatment timing.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).